Drug Profile
Research programme: interferon alpha-2b extended release - GeneMedix/SkyePharma
Latest Information Update: 02 May 2007
Price :
$50
*
At a glance
- Originator GeneMedix; SkyePharma PLC
- Class Interferons
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer; Hepatitis B; Hepatitis C